Cargando…
The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen
BACKGROUND: The accuracy of the conclusions from in vivo efficacy anti-malarial drug trials depends on distinguishing between recrudescences and re-infections which is accomplished by genotyping genes coding P. falciparum merozoite surface 1 (MSP1) and MSP2. However, the reliability of the PCR analy...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701615/ https://www.ncbi.nlm.nih.gov/pubmed/23861823 http://dx.doi.org/10.1371/journal.pone.0067853 |
_version_ | 1782275676952330240 |
---|---|
author | Al-abd, Nazeh M. Mahdy, Mohammed A. K. Al-Mekhlafi, Abdulsalam M. Q. Snounou, Georges Abdul-Majid, Nazia B. Al-Mekhlafi, Hesham M. Fong, Mun Y. |
author_facet | Al-abd, Nazeh M. Mahdy, Mohammed A. K. Al-Mekhlafi, Abdulsalam M. Q. Snounou, Georges Abdul-Majid, Nazia B. Al-Mekhlafi, Hesham M. Fong, Mun Y. |
author_sort | Al-abd, Nazeh M. |
collection | PubMed |
description | BACKGROUND: The accuracy of the conclusions from in vivo efficacy anti-malarial drug trials depends on distinguishing between recrudescences and re-infections which is accomplished by genotyping genes coding P. falciparum merozoite surface 1 (MSP1) and MSP2. However, the reliability of the PCR analysis depends on the genetic markers’ allelic diversity and variant frequency. In this study the genetic diversity of the genes coding for MSP1 and MSP2 was obtained for P. falciparum parasites circulating in Yemen. METHODS: Blood samples were collected from 511 patients with fever and screened for malaria parasites using Giemsa-stained blood films. A total 74 samples were infected with P. falciparum, and the genetic diversity was assessed by nested PCR targeting Pfmsp1 (Block2) and Pfmsp2 (block 3). RESULTS: Overall, 58%, 28% and 54% of the isolates harboured parasites of the Pfmsp1 K1, MAD20 and RO33 allelic families, and 55% and 89% harboured those of the Pfmsp2 FC27 and 3D7 allelic families, respectively. For both genetic makers, the multiplicity of the infection (MOI) was significantly higher in the isolates from the foothills/coastland areas as compared to those from the highland (P<0.05). Pfmsp2 had higher number of distinct allelic variants than Pfmsp1 (20 vs 11). The expected heterozygosity (HE) for Pfmsp1 and Pfmsp2 were 0.82 and 0.94, respectively. Nonetheless, a bias in the frequency distribution of the Pfmsp1 allelic variants was noted from all areas, and of those of Pfmsp2 in the samples collected from the highland areas. CONCLUSIONS: Significant differences in the complexity and allelic diversity of Pfmsp1 and Pfmsp2 genes between areas probably reflect differences in the intensity of malaria transmission. The biased distribution of allelic variants suggests that in Yemen Pfmsp1 should not be used for PCR correction of in vivo clinical trials outcomes, and that caution should be exercised when employing Pfmsp2. |
format | Online Article Text |
id | pubmed-3701615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37016152013-07-16 The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen Al-abd, Nazeh M. Mahdy, Mohammed A. K. Al-Mekhlafi, Abdulsalam M. Q. Snounou, Georges Abdul-Majid, Nazia B. Al-Mekhlafi, Hesham M. Fong, Mun Y. PLoS One Research Article BACKGROUND: The accuracy of the conclusions from in vivo efficacy anti-malarial drug trials depends on distinguishing between recrudescences and re-infections which is accomplished by genotyping genes coding P. falciparum merozoite surface 1 (MSP1) and MSP2. However, the reliability of the PCR analysis depends on the genetic markers’ allelic diversity and variant frequency. In this study the genetic diversity of the genes coding for MSP1 and MSP2 was obtained for P. falciparum parasites circulating in Yemen. METHODS: Blood samples were collected from 511 patients with fever and screened for malaria parasites using Giemsa-stained blood films. A total 74 samples were infected with P. falciparum, and the genetic diversity was assessed by nested PCR targeting Pfmsp1 (Block2) and Pfmsp2 (block 3). RESULTS: Overall, 58%, 28% and 54% of the isolates harboured parasites of the Pfmsp1 K1, MAD20 and RO33 allelic families, and 55% and 89% harboured those of the Pfmsp2 FC27 and 3D7 allelic families, respectively. For both genetic makers, the multiplicity of the infection (MOI) was significantly higher in the isolates from the foothills/coastland areas as compared to those from the highland (P<0.05). Pfmsp2 had higher number of distinct allelic variants than Pfmsp1 (20 vs 11). The expected heterozygosity (HE) for Pfmsp1 and Pfmsp2 were 0.82 and 0.94, respectively. Nonetheless, a bias in the frequency distribution of the Pfmsp1 allelic variants was noted from all areas, and of those of Pfmsp2 in the samples collected from the highland areas. CONCLUSIONS: Significant differences in the complexity and allelic diversity of Pfmsp1 and Pfmsp2 genes between areas probably reflect differences in the intensity of malaria transmission. The biased distribution of allelic variants suggests that in Yemen Pfmsp1 should not be used for PCR correction of in vivo clinical trials outcomes, and that caution should be exercised when employing Pfmsp2. Public Library of Science 2013-07-04 /pmc/articles/PMC3701615/ /pubmed/23861823 http://dx.doi.org/10.1371/journal.pone.0067853 Text en © 2013 Al-abd et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Al-abd, Nazeh M. Mahdy, Mohammed A. K. Al-Mekhlafi, Abdulsalam M. Q. Snounou, Georges Abdul-Majid, Nazia B. Al-Mekhlafi, Hesham M. Fong, Mun Y. The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen |
title | The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen |
title_full | The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen |
title_fullStr | The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen |
title_full_unstemmed | The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen |
title_short | The Suitability of P. falciparum Merozoite Surface Proteins 1 and 2 as Genetic Markers for In Vivo Drug Trials in Yemen |
title_sort | suitability of p. falciparum merozoite surface proteins 1 and 2 as genetic markers for in vivo drug trials in yemen |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701615/ https://www.ncbi.nlm.nih.gov/pubmed/23861823 http://dx.doi.org/10.1371/journal.pone.0067853 |
work_keys_str_mv | AT alabdnazehm thesuitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT mahdymohammedak thesuitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT almekhlafiabdulsalammq thesuitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT snounougeorges thesuitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT abdulmajidnaziab thesuitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT almekhlafiheshamm thesuitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT fongmuny thesuitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT alabdnazehm suitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT mahdymohammedak suitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT almekhlafiabdulsalammq suitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT snounougeorges suitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT abdulmajidnaziab suitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT almekhlafiheshamm suitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen AT fongmuny suitabilityofpfalciparummerozoitesurfaceproteins1and2asgeneticmarkersforinvivodrugtrialsinyemen |